TCR2 Therapeutics to Present at the UBS Global Healthcare Conference and the Jefferies 2018 Global Healthcare Conference -

CAMBRIDGE, Mass., May 14, 2018 /PRNewswire/ -- TCR2 Therapeutics Inc., an immuno-oncology company pioneering a novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, announced today that its Chief Executive Officer, Garry E. Menzel, PhD, will...

read more

In related news